Sitagliptin
- Generic Name
- Sitagliptin
- Brand Names
- Janumet, Januvia, Ristaben, Steglujan, Tesavel, Velmetia, Xelevia, Sitagliptin SUN, Sitagliptin Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15F6N5O
- CAS Number
- 486460-32-6
- Unique Ingredient Identifier
- QFP0P1DV7Z
- Background
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar. Sitagliptin was granted FDA approval on October 16, 2006.
- Indication
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.
It is also used in combination with metformin or ertugliflozin.
- Associated Conditions
- Type 2 Diabetes Mellitus
An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2004-10-25
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 521
- Registration Number
- NCT00094757
Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2004-07-13
- Last Posted Date
- 2015-07-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 741
- Registration Number
- NCT00087516
Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)
- Conditions
- Diabetes Mellitus, Type II
- Interventions
- First Posted Date
- 2004-07-05
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 701
- Registration Number
- NCT00086515
Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2004-07-05
- Last Posted Date
- 2016-02-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 353
- Registration Number
- NCT00086502
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.